The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hemofiltration


High impact information on Hemofiltration


Chemical compound and disease context of Hemofiltration


Biological context of Hemofiltration


Anatomical context of Hemofiltration


Associations of Hemofiltration with chemical compounds


Gene context of Hemofiltration

  • Pre-filter (afferent), post-filter (efferent) and ultrafiltrate concentrations of cytokines (IL-1 beta, IL-6, IL-8, TNF alpha) and of complement components (C3, C3adesArg, C5adesArg, terminal complement complex) were measured after the beginning of hemofiltration (t0), and 60 minutes later (t60) [29].
  • In conclusion, the reduction in TNF-alpha, IL-6 and IL-8 was most impressive with the polyacrylonitrile membrane after 4 h of hemofiltration and was largely due to adsorption [30].
  • The median sieving coefficient (SC) for all membranes was 0.0 for TNF-alpha, below 0.15 for IL-6 and below 0.15 for IL-8 during postdilution hemofiltration [30].
  • Hemofiltered patients showed higher TM plasma levels, which further increased during the hemofiltration procedure [31].
  • Interleukin-1 (IL-1) increased slowly at the end of CPB and hemofiltration had no effect [32].

Analytical, diagnostic and therapeutic context of Hemofiltration


  1. Hemofiltration for digoxin toxicity. Doherty, J. Arch. Intern. Med. (1986) [Pubmed]
  2. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Tegeder, I., Neumann, F., Bremer, F., Brune, K., Lötsch, J., Geisslinger, G. Clin. Pharmacol. Ther. (1999) [Pubmed]
  3. Massive plasma arginine vasopressin (AVP) removal during hemofiltration stimulates AVP secretion in humans. Pruszczynski, W., Viron, B., Mignon, F., Ardaillou, R. J. Clin. Endocrinol. Metab. (1987) [Pubmed]
  4. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Palsson, R., Niles, J.L. Kidney Int. (1999) [Pubmed]
  5. Effects of human thyroxine-binding globulin and prealbumin on the reverse flow of thyroid hormones from extravascular space into the bloodstream in rabbits. Wahl, R., Schmidberger, H., Fessler, E., Heinzel, W., Schenzle, D., Bohner, J., Kallee, E. Endocrinology (1989) [Pubmed]
  6. Fulminant Wilson's disease treated with postdilution hemofiltration and orthotopic liver transplantation. Rakela, J., Kurtz, S.B., McCarthy, J.T., Ludwig, J., Ascher, N.L., Bloomer, J.R., Claus, P.L. Gastroenterology (1986) [Pubmed]
  7. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration. Domoto, D.T., Brown, W.W., Bruggensmith, P. Ann. Intern. Med. (1987) [Pubmed]
  8. Continuous arteriovenous hemofiltration in the critically ill patient. Clinical use and operational characteristics. Lauer, A., Saccaggi, A., Ronco, C., Belledonne, M., Glabman, S., Bosch, J.P. Ann. Intern. Med. (1983) [Pubmed]
  9. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. Pingpank, J.F., Libutti, S.K., Chang, R., Wood, B.J., Neeman, Z., Kam, A.W., Figg, W.D., Zhai, S., Beresneva, T., Seidel, G.D., Alexander, H.R. J. Clin. Oncol. (2005) [Pubmed]
  10. Continuous venovenous hemofiltration with dialysis and lactate clearance in critically ill patients. Benjamin, E. Crit. Care Med. (1997) [Pubmed]
  11. Removal of intracellular waste products by hemofiltration. Kimura, G., Kojima, S., Kawano, Y., Imanishi, M., Kuramochi, M., Omae, T. Am. J. Kidney Dis. (1989) [Pubmed]
  12. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Capellier, G., Cornette, C., Boillot, A., Guinchard, C., Jacques, T., Blasco, G., Barale, F. Crit. Care Med. (1998) [Pubmed]
  13. Cerebral blood flow and oxygenation in liver transplantation for acute or chronic hepatic disease without venovenous bypass. Pere, P., Höckerstedt, K., Isoniemi, H., Lindgren, L. Liver Transpl. (2000) [Pubmed]
  14. Cytokines clearance during venovenous hemofiltration in the trauma patient. Sanchez-Izquierdo, J.A., Perez Vela, J.L., Lozano Quintana, M.J., Alted Lopez, E., Ortuño de Solo, B., Ambros Checa, A. Am. J. Kidney Dis. (1997) [Pubmed]
  15. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Thalhammer, F., Schenk, P., Burgmann, H., El Menyawi, I., Hollenstein, U.M., Rosenkranz, A.R., Sunder-Plassmann, G., Breyer, S., Ratheiser, K. Antimicrob. Agents Chemother. (1998) [Pubmed]
  16. Drug protein binding in chronic renal failure: evaluation of nine drugs. Vanholder, R., Van Landschoot, N., De Smet, R., Schoots, A., Ringoir, S. Kidney Int. (1988) [Pubmed]
  17. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Reeves, J.H., Cumming, A.R., Gallagher, L., O'Brien, J.L., Santamaria, J.D. Crit. Care Med. (1999) [Pubmed]
  18. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. Kozek-Langenecker, S.A., Spiss, C.K., Michalek-Sauberer, A., Felfernig, M., Zimpfer, M. Crit. Care Med. (2003) [Pubmed]
  19. The impact of lactate-buffered high-volume hemofiltration on acid-base balance. Cole, L., Bellomo, R., Baldwin, I., Hayhoe, M., Ronco, C. Intensive care medicine. (2003) [Pubmed]
  20. Removal, generation and adsorption of beta-2-microglobulin during hemofiltration with five different membranes. Jørstad, S., Smeby, L.C., Balstad, T., Widerøe, T.E. Blood Purif. (1988) [Pubmed]
  21. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Dünser, M.W., Fries, D.R., Schobersberger, W., Ulmer, H., Wenzel, V., Friesenecker, B., Hasibeder, W.R., Mayr, A.J. Anesth. Analg. (2004) [Pubmed]
  22. Changes in circulating norepinephrine with hemofiltration in advanced congestive heart failure. Cipolla, C.M., Grazi, S., Rimondini, A., Susini, G., Guazzi, M., Della Bella, P., Guazzi, M.D. Am. J. Cardiol. (1990) [Pubmed]
  23. Commercially available media for flushing extracorporeal bioartificial liver systems prior to connection to the patient's circulation: an in vitro comparative study in two and three dimensional porcine hepatocyte cultures. Flendrig, L.M., Sommeijer, D., Ladiges, N.C., Te Velde, A.A., Maas, M.A., Jörning, G.G., Daalhuisen, J., Chamuleau, R.A. The International journal of artificial organs. (1998) [Pubmed]
  24. Low-molecular-weight heparin for anticoagulation during continuous venovenous hemofiltration. Knight, D.J., Selwyn, D., Girling, K. Arch. Intern. Med. (2003) [Pubmed]
  25. Studies of carbohydrate metabolism after hemodialysis and hemofiltration in uremic patients. Geronemus, R., Bosch, J.P., Thornton, J., Rayfield, E.J. Arch. Intern. Med. (1982) [Pubmed]
  26. Hemofiltration in digoxin overdose. Lai, K.N., Swaminathan, R., Pun, C.O., Vallance-Owen, J. Arch. Intern. Med. (1986) [Pubmed]
  27. Clinical manifestations and management of acute lithium intoxication. Okusa, M.D., Crystal, L.J. Am. J. Med. (1994) [Pubmed]
  28. Antidiuretic hormone in congestive heart failure. Riegger, G.A., Liebau, G., Kochsiek, K. Am. J. Med. (1982) [Pubmed]
  29. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Hoffmann, J.N., Hartl, W.H., Deppisch, R., Faist, E., Jochum, M., Inthorn, D. Kidney Int. (1995) [Pubmed]
  30. Cytokine filtration and adsorption during pre- and postdilution hemofiltration in four different membranes. Bouman, C.S., van Olden, R.W., Stoutenbeek, C.P. Blood Purif. (1998) [Pubmed]
  31. Thrombomodulin in intensive care patients. Boldt, J., Wollbrück, T., Sonneborn, S., Welters, A., Hempelmann, G. Intensive care medicine. (1995) [Pubmed]
  32. Inflammatory cytokines in pediatric cardiac surgery and variable effect of the hemofiltration process. Brancaccio, G., Villa, E., Girolami, E., Michielon, G., Feltri, C., Mazzera, E., Costa, D., Isacchi, G., Iannace, E., Amodeo, A., Di Donato, R.M. Perfusion (2005) [Pubmed]
  33. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Schrader, J., Stibbe, W., Armstrong, V.W., Kandt, M., Muche, R., Köstering, H., Seidel, D., Scheler, F. Kidney Int. (1988) [Pubmed]
  34. Kinetics of 125I-beta 2-microglobulin turnover in dialyzed patients. Vincent, C., Chanard, J., Caudwell, V., Lavaud, S., Wong, T., Revillard, J.P. Kidney Int. (1992) [Pubmed]
  35. Is low-molecular-weight heparin useful for venovenous hemofiltration in the intensive care unit? Spiegel, D.M., Anderson, R.J. Crit. Care Med. (1999) [Pubmed]
  36. Effect of continuous hemofiltration on phenytoin elimination. Lau, A.H., Kronfol, N.O. Therapeutic drug monitoring. (1994) [Pubmed]
WikiGenes - Universities